Literature DB >> 22652681

An organ system based approach to prognosis in advanced melanoma.

Shernan G Holtan1, Aaron S Mansfield, Douglas J Creedon, Wendy K Nevala, Paul Haluska, Alexey A Leontovich, Svetomir N Markovic.   

Abstract

Previous models to study the biology of melanoma have focused on individual factors, such as proliferative and invasive capacity, the microenvironment, angiogenesis, or systemic immune dysfunction. However, all of these factors contribute to melanoma progression in concert. One physiologic phenomenon that typifies the coordination of these processes is placental development, characterized by trophoblast proliferation, invasion into decidual tissues, angiogenesis, and transient organ system-based immune evasion. Herein, we explore expression of 34 proteins involved in placentation and determine their association with an established prognostic factor, tumor infiltrating lymphocytes (TILs), in a 118-patient tumor microarray (TMA). Melanoma expression of CD58 and galectin-9 independently predicted for a favorable prognosis. Patients could be categorized into three clusters based upon patterns of protein expression and TILs. Patients in Cluster 2 demonstrated frequent TILs and superior overall survival. Pathway enrichment using MetaCore (trademark) from GeneGo, a Thompson Reuters company, showed that TIMP2 and CD44 were expressed more frequently within Cluster 2 patients, suggesting a potential association with TILs. A subset of melanoma patients appear to lack an organized immune response to the tumor, which portends a poor prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22652681     DOI: 10.2741/e586

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  6 in total

Review 1.  Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Authors:  Elizabeth Ann L Enninga; Shernan G Holtan; Douglas J Creedon; Roxana S Dronca; Wendy K Nevala; Simona Ognjanovic; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

2.  Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.

Authors:  Elizabeth Ann L Enninga; Wendy K Nevala; Shernan G Holtan; Alexey A Leontovich; Svetomir N Markovic
Journal:  Melanoma Res       Date:  2016-10       Impact factor: 3.599

Review 3.  Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics.

Authors:  Elizabeth Ann L Enninga; Wendy K Nevala; Shernan G Holtan; Svetomir N Markovic
Journal:  Front Immunol       Date:  2015-08-26       Impact factor: 7.561

Review 4.  Tim-3 finds its place in the cancer immunotherapy landscape.

Authors:  Nandini Acharya; Catherine Sabatos-Peyton; Ana Carrizosa Anderson
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 5.  Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis.

Authors:  Qiaofen Fu; Nan Chen; Chunlei Ge; Ruilei Li; Zhen Li; Baozhen Zeng; Chunyan Li; Ying Wang; Yuanbo Xue; Xin Song; Heng Li; Gaofeng Li
Journal:  Oncoimmunology       Date:  2019-04-03       Impact factor: 8.110

6.  Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis.

Authors:  Xiaoxiang Zhou; Lejia Sun; Dan Jing; Gang Xu; Jinmei Zhang; Li Lin; Jingjing Zhao; Zhuoran Yao; Hongfeng Lin
Journal:  Front Physiol       Date:  2018-04-26       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.